BioMarin Pharmaceutical Inc. buy UBS Group AG
Start price
30.10.24
/
50%
€62.34
Target price
30.10.25
€97.65
Performance (%)
-28.01%
End price
31.10.25
€44.88
Summary
This prediction ended on 31.10.25 with a price of €44.88. The prediction for BioMarin Pharmaceutical Inc. disappointed with a performance of -28.01%. UBS_Group_AG has a follow-up prediction for BioMarin Pharmaceutical Inc. where he still thinks BioMarin Pharmaceutical Inc. is a Buy. UBS_Group_AG has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| BioMarin Pharmaceutical Inc. | -3.367% | -3.367% | -7.518% |
| iShares Core DAX® | 2,55 % | -0,11 % | 15,00 % |
| iShares Nasdaq 100 | 2,74 % | -0,47 % | 30,95 % |
| iShares Nikkei 225® | 6,58 % | 3,22 % | 49,70 % |
| iShares S&P 500 | 1,93 % | -0,52 % | 24,88 % |
Comments by UBS_Group_AG for this prediction
In the thread BioMarin Pharmaceutical Inc. diskutieren
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at UBS Group AG from $104.00 to $106.00. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
In the thread Trading BioMarin Pharmaceutical Inc.
Die von UBS_Group_AG gewählte maximale Laufzeit wurde überschritten
Current prediction by UBS_Group_AG for BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€51.06
05.08.25
05.08.25
€98.62
05.08.26
05.08.26
-8.93%
10.04.26
10.04.26
Stopped prediction by UBS_Group_AG for BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€65.70
20.02.25
20.02.25
€108.05
20.02.26
20.02.26
-18.54%
21.02.26
21.02.26